

FILED COPY

1 Tyler J. Woods (State Bar No. 232464)  
twoods@trialnewport.com  
2 Richard H. Hikida (State Bar No. 196149)  
rhikida@trialnewport.com  
3 Scott J. Ferrell (State Bar No. 202091)  
sferrell@trialnewport.com

2012 OCT 22 PM 1:36  
CLERK, U.S. DISTRICT COURT  
CENTRAL DIST. OF CALIF.  
LOS ANGELES

4 **NEWPORT TRIAL GROUP**  
A Professional Corporation  
5 895 Dove Street, Suite 425  
Newport Beach, CA 92660  
6 Tel: (949) 706-6464  
Fax: (949) 706-6469

BY \_\_\_\_\_

7 Attorneys for Plaintiff  
8

9 **UNITED STATES DISTRICT COURT**  
10 **CENTRAL DISTRICT OF CALIFORNIA**

11  
12 THE TAWNSAURA GROUP, LLC,  
13 Plaintiff,  
14 vs.  
15 TWINLAB CORPORATION,  
16 Defendant

Case No. SACV12-1467 SJO(AGR<sub>x</sub>)  
**FIRST AMENDED COMPLAINT FOR  
PATENT INFRINGEMENT**  
**JURY TRIAL DEMANDED**

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

1 Plaintiff The Tawnsaura Group, LLC (“Plaintiff”) hereby alleges for its First  
2 Amended Complaint against Twinlab Corporation (“Defendant”), on personal  
3 knowledge as to its own activities and on information and belief as to the activities of  
4 others, as follows:

5 **I. THE PARTIES**

6 1. Plaintiff is a limited liability company organized and existing under the  
7 laws of Nevada, with a registered office at 50 West Liberty Street, Suite 1100, Reno,  
8 Nevada 89501.

9 2. Plaintiff is the owner and assignee of United States Patent No. 5,874,471  
10 (“the ‘471 patent”) titled “Orthomolecular Medical Use of L-Citrulline for  
11 Vasoprotection, Relaxative Smooth Muscle Tone and Cell Protection,” and United  
12 States Patent No. 6,028,107 (“the ‘107 patent”) titled “Orthomolecular Medical Use of  
13 L-Citrulline for Vasoprotection, Relaxative Smooth Muscle Tone and Cell Protection,”  
14 and Plaintiff licenses the ‘471 patent and the ‘107 patent to at least one third-party and  
15 is in negotiations to license the patents to numerous other parties.

16 3. Upon information and belief, Defendant Twinlab Corporation is a  
17 corporation organized and existing under the laws of New York with a principal place  
18 of business at 632 Broadway, Suite 201 in New York, New York, 10012.

19 **II. JURISDICTION AND VENUE**

20 4. This is an action for patent infringement arising under the patent laws of  
21 the United States, Title 35 of the United States Code. Accordingly, this Court has  
22 subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338, and 1367.

23 5. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400.

24 6. This Court has personal jurisdiction over Defendant. Defendant, directly  
25 or through intermediaries (including distributors, retailers, and others), ships,  
26 distributes, offers for sale, sells, and advertises its nutritional supplement products in  
27 the United States, the State of California, and the Central District of California,  
28 including the products sold as “Nitric Fuel Strength & Pump Dual Layer Tablets.”

1 Defendant has purposefully and voluntarily placed these products into the stream of  
2 commerce with the expectation that they will be purchased in the Central District of  
3 California.

4 **III. THE DEFENDANT'S INFRINGING PRODUCTS**

5 7. The label and/or advertisements for Defendant's Nitric Fuel Strength &  
6 Pump Dual Layer Tablets state that the products contain, *inter alia*, the ingredient  
7 "Citrulline Malate" and "kick-starts your workout using breakthrough fast-dissolve  
8 technology to flood muscles with cell-volumizing nitric oxide." Nitric Fuel Strength &  
9 Pump Dual Layer Tablets contains the ingredient l-citrulline.

10 8. As set forth herein, the above products infringe the claimed methods of the  
11 '471 patent and the '107 patent, and are therefore referred to herein as "the products  
12 that infringe the claimed methods."

13 9. Defendant has committed the tort of patent infringement within the State  
14 of California, and more particularly, within the Central District of California, by virtue  
15 of the fact that Defendant has shipped, distributed, offered for sale, sold, and advertised,  
16 and continues to ship, distribute, offer for sale, sell, and advertise the products that  
17 infringe the claimed methods in this District.

18 **IV. THE DEFENDANT'S INFRINGEMENTS**

19 10. Defendant's employees, agents, representatives and other persons  
20 sponsored by or who endorse Defendant and Defendant's products in advertising and  
21 marketing activities, including the football player Ray Lewis, have taken, used, and  
22 orally administered the products that infringe the claimed methods which have the  
23 effect, without limitation, of increasing the plasma level of arginine in the persons  
24 taking the products from a low or normal fasting level to a level which is up to three  
25 times an average overnight fasting level and increasing the plasma concentration of  
26 arginine in the persons taking the products from a low or normal fasting concentration  
27 to a level which is up to three times an average overnight fasting arginine level of about  
28 90 mu.mole per liter of plasma. These persons included persons who, without

1 limitation, were in good health, were in a condition of increased or continuing brain or  
2 neural activities, or were in a condition of increased or continuing muscular activities.  
3 Defendant has encouraged and/or is aware of these persons' oral administration of the  
4 products that infringe the claimed methods for these purposes, and these persons are  
5 acting under Defendant's direction and control. Therefore, Defendant practices the  
6 methods as set forth in the '471 patent and the '107 patent and is a direct infringer of  
7 the patents.

8 11. End-users of Defendant's products that infringe the claimed methods are  
9 also direct infringers of the '471 patent and the '107 patent, because they have taken,  
10 used, and orally administered the products that infringe the claimed methods which  
11 have the effect, without limitation, of increasing the plasma level of arginine in the  
12 persons taking the products from a low or normal fasting level to a level which is up to  
13 three times an average overnight fasting level and/or increasing the plasma  
14 concentration of arginine in the persons taking the products from a low or normal  
15 fasting concentration to a level which is up to three times an average overnight fasting  
16 arginine level of about 90 mu.mole per liter of plasma. These persons included persons  
17 who, without limitation, were in good health, were in a condition of increased or  
18 continuing brain or neural activities, or were in a condition of increased or continuing  
19 muscular activities. Therefore, they practice the methods as set forth in the '471 patent  
20 and the '107 patent.

21 12. For example and without limitation, a consumer known as "kwilliamson"  
22 wrote a review regarding his/her use of Nitric Fuel Strength & Pump Dual Layer  
23 Tablets on [http://reviews.bodybuilding.com/Twinlab/Nitric\\_Fuel](http://reviews.bodybuilding.com/Twinlab/Nitric_Fuel) and indicated that "I  
24 always get a great pump off of this product." This is just one of many end-users of  
25 Defendant's infringing products who has practiced the methods as set forth in the '471  
26 patent and the '107 patent and is directly infringing the patents.

27 13. Defendant's labels and advertising for the products that infringe the  
28 claimed methods explain the elements and essential elements of the methods disclosed

1 in the '471 patent and the '107 patent to end-users and encourage, urge, and induce the  
2 products' end-users to purchase and orally administer the products to practice those  
3 methods, and end-users do practice those methods. Defendant has therefore  
4 specifically intended to cause these end-users to directly infringe the claimed methods  
5 of the patents, and has urged them to do so.

6 14. Defendant's products that infringe the claimed methods are not suitable for  
7 non-infringing uses, and none of Defendant's labels or advertisements for the products  
8 disclose any uses for the products nor for the citrulline in those products that do not  
9 infringe upon the methods disclosed in the '471 patent and the '107 patent. The  
10 inclusion of the citrulline content in the products are, in fact, material to practicing the  
11 methods disclosed in the '471 patent and the '107 patent.

12 15. Defendant has knowledge that its products that infringe the claimed  
13 methods are especially adapted by end-users of the products for the practicing of the  
14 methods disclosed in the '471 patent and '107 patent, and, indeed, Defendant  
15 encourages, urges, and induces the products' end-users to purchase and orally  
16 administer the products to practice those methods, and has done so in the past.

17 16. Defendant has intentionally and knowingly induced, encouraged, and  
18 urged end-users of the products that infringe the claimed methods to purchase and  
19 orally administer the products for the purpose, without limitation, of increasing the  
20 plasma level of arginine in the persons taking the products from a low or normal fasting  
21 level to a level which is up to three times an average overnight fasting level and  
22 increasing the plasma concentration of arginine in the persons taking the products from  
23 a low or normal fasting concentration to a level which is up to three times an average  
24 overnight fasting arginine level of about 90 mu.mole per liter of plasma, including by  
25 end-users who, without limitation, were in good health, were in a condition of increased  
26 or continuing brain or neural activities, or were in a condition of increased or  
27 continuing muscular activities.

28

1           17. On information and belief, Defendant had actual, first-hand knowledge of  
2 the '471 patent and the '107 patent as early as the time Defendant launched each of the  
3 products that infringe the claimed methods in the marketplace. Defendant employs and  
4 engages sophisticated, experienced legal counsel with expertise in patent law.  
5 Defendant, through its counsel, conducts or should conduct due diligence on the  
6 potential for Defendant's products to infringe on patents and knew or should have  
7 known that the products that infringe the claimed methods actually infringe or could  
8 infringe on the '471 patent and '107 patent, but Defendant decided to infringe the  
9 patents anyway or ignored the risk of infringement.

10           18. In the alternative, Plaintiff pleads that Defendant subjectively believed at  
11 the time Defendant launched each of the products that infringe the claimed methods in  
12 the marketplace that there is or was a high probability of the fact that patents existed  
13 that covered the use of citrulline as in the products and that Defendant took deliberate  
14 actions to avoid confirming that fact, including not conducting due diligence as to  
15 potential patent infringements. Defendant therefore willfully blinded itself to the  
16 infringing nature of its sales of the products that infringe the claimed methods.

17           19. At a minimum, Defendant became aware of the '471 patent and the '107  
18 patent at the time of the filing of the initial Complaint in this matter and the receipt of  
19 Plaintiff's counsel's letter regarding the suit. Defendant has not ceased its own direct  
20 infringement, contributory infringement, or inducement of infringements by end-users  
21 despite such knowledge.

22           20. The earliest exact date Defendant obtained knowledge of the '471 patent  
23 and the '107 patent is within the exclusive possession and control of Defendant.  
24 However, Defendant specifically induces end-users to use its products, and particularly  
25 the citrulline component in the products, for increasing nitric oxide levels, "pump," and  
26 muscle volume and Defendant knows and intends that end-users achieve those  
27 objectives by practicing the methods as set forth in the '471 and '107 patents. This is  
28 why Defendant includes citrulline in its products – for the purposes of improving of the

1 health of end-users to increase the plasma level of arginine in end-users to a level from  
2 a low or normal fasting level to a level which is up to three times an average overnight  
3 fasting level, and improving the health of end-users to increase the plasma  
4 concentration of arginine in the subject to a level from a low or normal fasting  
5 concentration to a level which is up to three times an average overnight fasting arginine  
6 level of about 90 mu.mole per liter of plasma – and Defendant knows that end-users  
7 purchase and ingest the products, and particularly the citrulline content of the products,  
8 for those purposes. Defendant’s infringing activities have not stopped despite its  
9 knowledge of the patents’ existence.

10 **V. FIRST CAUSE OF ACTION**

11 **Infringement of U.S. Patent No. 5,874,471**

12 21. Plaintiff repeats and re-alleges the allegations of the foregoing paragraphs  
13 of this First Amended Complaint as if fully set forth herein.

14 22. Defendant has in the past and still is literally infringing or infringing under  
15 the doctrine of equivalents, directly and indirectly through contributory and/or induced  
16 infringement, one or more claims of the ‘471 patent by making, using, selling, and  
17 offering for sale nutritional supplements embodying the patented invention, and will  
18 continue to do so unless enjoined by this Court.

19 23. The claims of the ‘471 patent infringed by Defendant include claims 1, 2,  
20 20, 21, and 28.

21 24. Examples of Defendant’s direct infringement includes, without limitation,  
22 the fact that Defendant’s employees, agents, representatives and other persons  
23 sponsored by or who endorse Defendant and Defendant’s products in advertising and  
24 marketing activities, have taken, used, and orally administered the products that  
25 infringe the claimed methods which have the effect, without limitation, of increasing  
26 the plasma level of arginine in the persons taking the products from a low or normal  
27 fasting level to a level which is up to three times an average overnight fasting level.  
28 These persons included persons who, without limitation, were in good health, were in a

1 condition of increased or continuing brain or neural activities, or were in a condition of  
2 increased or continuing muscular activities. Defendant has encouraged and/or is aware  
3 of these persons' oral administration of the products that infringe the claimed methods  
4 for these purposes, these persons are acting under Defendant's direction and control,  
5 and therefore Defendant is directly practicing the methods set forth in the '471 patent.

6 25. End-users of Defendant's products that infringe the claimed methods are  
7 also direct infringers of the '471 patent, because they have taken, used, and orally  
8 administered the products that infringe the claimed methods which have the effect,  
9 without limitation, of increasing the plasma level of arginine in the persons taking the  
10 products from a low or normal fasting level to a level which is up to three times an  
11 average overnight fasting level. These persons included persons who, without  
12 limitation, were in good health, were in a condition of increased or continuing brain or  
13 neural activities, or were in a condition of increased or continuing muscular activities.  
14 Therefore, they practice the methods as set forth in the '471 patent.

15 26. Defendant's labels and advertising for the products that infringe the  
16 claimed methods explain the elements or essential elements of the methods disclosed in  
17 the '471 patent to end-users and encourage, urge, and induce the products' end-users to  
18 purchase and orally administer the products to practice those methods. Defendant's  
19 products that infringe the claimed methods are not suitable for non-infringing uses, and  
20 none of Defendant's labels or advertisements for the products disclose any uses for the  
21 relevant ingredients in the products that have a use that does not infringe upon the  
22 methods disclosed in the '471 patent. Defendant has knowledge that its products that  
23 infringe the claimed methods are especially adapted by end-users of the products for the  
24 practicing of the method disclosed in the '471 patent, as Defendant encourages, urges,  
25 and induces the products' end-users to purchase and orally administer the products to  
26 practice those methods, and has done so in the past. Defendant therefore is liable for  
27 contributory infringement of one or more claims of the '471 patent.

28



1           27. Defendant has intentionally and knowingly induced, encouraged, and  
2 urged end-users of the products that infringe the claimed methods to purchase and  
3 orally administer the products for the purpose, without limitation, of increasing the  
4 plasma level of arginine in the persons taking the products from a low or normal fasting  
5 level to a level which is up to three times an average overnight fasting level, including  
6 by end-users who, without limitation, were in good health, were in a condition of  
7 increased or continuing brain or neural activities, or were in a condition of increased or  
8 continuing muscular activities. On information and belief, Defendant had actual, first-  
9 hand knowledge of the '471 patent as early as the time Defendant launched each of the  
10 products that infringe the claimed methods in the marketplace. In the alternative, and  
11 on information and belief, Plaintiff pleads that Defendant subjectively believed at the  
12 time Defendant launched each of the products that infringe the claimed methods in the  
13 marketplace that there is or was a high probability of the fact that patents existed that  
14 covered the use of citrulline as in the products that infringe the claimed methods, and  
15 that Defendant took deliberate actions to avoid confirming that fact. Defendant  
16 therefore willfully blinded itself to the infringing nature of its sales of the products that  
17 infringe the claimed methods. At a minimum, Plaintiff pleads that Defendant became  
18 aware of the '471 patent at the time of the filing of the initial Complaint in this matter,  
19 and the issuance of a correspondence from Plaintiff's counsel regarding the suit.  
20 Defendant has not ceased its contributory infringement or inducement of infringements  
21 by end-users despite such knowledge. Defendant is therefore liable for induced  
22 infringement of one or more of claims of the '471 patent.

23           28. Defendant's activities have been without express or implied license by  
24 Plaintiff.

25           29. The infringement by Defendant has been and continues to be willful, since  
26 the infringement has not ceased, particularly after the filing of the initial suit in this  
27 matter.  
28

1 30. As a result of Defendant's acts of infringement, Plaintiff has suffered and  
2 will continue to suffer damages in an amount to be proved at trial.

3 31. As a result of Defendant's acts of infringement, Plaintiff has been and will  
4 continue to be irreparably harmed by Defendant's infringement and inducement, which  
5 will continue unless Defendant is enjoined by this Court.

6 32. Plaintiff believes that Defendant's past infringement and/or continuing  
7 infringement has been deliberate and willful, and that this case is therefore an  
8 exceptional case, which warrants an award of treble damages and attorneys' fees in  
9 accordance with 35 U.S.C. § 285.

10 **VI. SECOND CAUSE OF ACTION**

11 **Infringement of U.S. Patent No. 6,028,107**

12 33. Plaintiff repeats and re-alleges the allegations of the foregoing paragraphs  
13 of this First Amended Complaint as if fully set forth herein.

14 34. Defendant has in the past and still is literally infringing or infringing under  
15 the doctrine of equivalents, directly and indirectly through contributory and/or induced  
16 infringement, one or more claims of the '107 patent by making, using, selling, and  
17 offering for sale nutritional supplements embodying the patented invention, and will  
18 continue to do so unless enjoined by this Court.

19 35. The claims of the '107 patent infringed by Defendant include claims 1, 2,  
20 15, and 16.

21 36. Examples of Defendant's direct infringement includes, without limitation,  
22 the fact that Defendant's employees, agents, representatives and other persons  
23 sponsored by or who endorse Defendant and Defendant's products in advertising and  
24 marketing activities, have taken, used, and orally administered the products that  
25 infringe the claimed methods which have the effect, without limitation, of increasing  
26 the plasma concentration of arginine in the persons taking the products from a low or  
27 normal fasting concentration to a level which is up to three times an average overnight  
28 fasting arginine level of about 90 mu.mole per liter of plasma. These persons included

1 persons who, without limitation, were in good health, were in a condition of increased  
2 or continuing brain or neural activities, or were in a condition of increased or  
3 continuing muscular activities. Defendant has encouraged and/or is aware of these  
4 persons' oral administration of the products that infringe the claimed methods for these  
5 purposes, these persons are acting under Defendant's direction and control, and  
6 therefore Defendant is directly practicing the methods set forth in the '107 patent.

7 37. End-users of Defendant's products that infringe the claimed methods are  
8 also direct infringers of the '107 patent, because they have taken, used, and orally  
9 administered the products that infringe the claimed methods which have the effect,  
10 without limitation, of increasing the plasma concentration of arginine in the persons  
11 taking the products from a low or normal fasting concentration to a level which is up to  
12 three times an average overnight fasting arginine level of about 90  $\mu$ mole per liter of  
13 plasma. These persons included persons who, without limitation, were in good health,  
14 were in a condition of increased or continuing brain or neural activities, or were in a  
15 condition of increased or continuing muscular activities. Therefore, they practice the  
16 methods as set forth in the '107 patent.

17 38. Defendant's labels and advertising for the products that infringe the  
18 claimed methods explain the elements or essential elements of the methods disclosed in  
19 the '471 patent to end-users and encourage, urge, and induce the products' end-users to  
20 purchase and orally administer the products to practice those methods. Defendant's  
21 products that infringe the claimed methods are not suitable for non-infringing uses, and  
22 none of Defendant's labels or advertisements for the products disclose any uses for the  
23 relevant ingredients in the products that have a use that does not infringe upon the  
24 methods disclosed in the '107 patent. Defendant has knowledge that its products that  
25 infringe the claimed methods are especially adapted by end-users of the products for the  
26 practicing of the method disclosed in the '107 patent, as Defendant encourages, urges,  
27 and induces the products' end-users to purchase and orally administer the products to  
28

1 practice those methods, and has done so in the past. Defendant therefore is liable for  
2 contributory infringement of one or more claims of the '107 patent.

3 39. Defendant has intentionally and knowingly induced, encouraged, and  
4 urged end-users of the products that infringe the claimed methods to purchase and  
5 orally administer the products for the purpose, without limitation, of increasing the  
6 plasma concentration of arginine in the persons taking the products from a low or  
7 normal fasting concentration to a level which is up to three times an average overnight  
8 fasting arginine level of about 90  $\mu$ mole per liter of plasma, including by end-users  
9 who, without limitation, were in good health, were in a condition of increased or  
10 continuing brain or neural activities, or were in a condition of increased or continuing  
11 muscular activities. On information and belief, Defendant had actual, first-hand  
12 knowledge of the '107 patent as early as the time Defendant launched each of the  
13 products that infringe the claimed methods in the marketplace. In the alternative, and  
14 on information and belief, Plaintiff pleads that Defendant subjectively believed at the  
15 time Defendant launched each of the products that infringe the claimed methods in the  
16 marketplace that there is or was a high probability of the fact that patents existed that  
17 covered the use of citrulline as in the products that infringe the claimed methods, and  
18 that Defendant took deliberate actions to avoid confirming that fact. Defendant  
19 therefore willfully blinded itself to the infringing nature of its sales of the products that  
20 infringe the claimed methods. At a minimum, Plaintiff pleads that Defendant became  
21 aware of the '107 patent at the time of the filing of the initial Complaint in this matter  
22 and the issuance of a correspondence from Plaintiff's counsel regarding the suit.  
23 Defendant has not ceased its contributory infringement or inducement of infringements  
24 by end-users despite such knowledge. Defendant is therefore liable for induced  
25 infringement of one or more of claims of the '107 patent.

26 40. Defendant's activities have been without express or implied license by  
27 Plaintiff.  
28

1 41. The infringement by Defendant has been and continues to be willful, since  
2 the infringement has not ceased, particularly after the filing of the initial suit in this  
3 matter.

4 42. As a result of Defendant's acts of infringement, Plaintiff has suffered and  
5 will continue to suffer damages in an amount to be proved at trial.

6 43. As a result of Defendant's acts of infringement, Plaintiff has been and will  
7 continue to be irreparably harmed by Defendant's infringement and inducement, which  
8 will continue unless Defendant is enjoined by this Court.

9 44. Plaintiff believes that Defendant's past infringement and/or continuing  
10 infringement has been deliberate and willful, and that this case is therefore an  
11 exceptional case, which warrants an award of treble damages and attorneys' fees in  
12 accordance with 35 U.S.C. § 285.

13 **VII. PRAYER FOR RELIEF**

14 WHEREFORE, Plaintiff prays for entry of judgment against Defendant as  
15 follows:

16 1. A declaration that Defendant has infringed the '471 patent and the '107  
17 patent under 35 U.S.C. §§ 271 *et seq.*;

18 3. That injunctions, preliminary and permanent, be issued by this Court  
19 restraining Defendant, its respective officers, agents, servants, directors, and employees,  
20 and all persons in active concert or participation with each, from directly or indirectly  
21 infringing, or inducing or contributing to the infringement by others of, the '471 patent  
22 and the '107 patent;

23 4. That Defendant be required to provide to Plaintiff an accounting of all  
24 gains, profits, and advantages derived by Defendant's infringement of the '471 patent  
25 and the '107 patent, and that Plaintiff be awarded damages adequate to compensate  
26 Plaintiff for the wrongful infringing acts by Defendant, in accordance with 35 U.S.C. §  
27 284;

28



**DEMAND FOR JURY TRIAL**

Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiff hereby demands a jury trial for all issues in this case that properly are subject to a jury trial.

Respectfully submitted,  
NEWPORT TRIAL GROUP  
A Professional Corporation



Dated: October 22, 2012

By: Scott J Ferrell  
Attorneys for Plaintiff

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

NAME, ADDRESS AND TELEPHONE NUMBER OF ATTORNEY(S)

Tyler J Woods, Bar No. 232464  
 Scott J Ferrell, Bar No. 202091  
 NEWPORT TRIAL GROUP  
 895 Dove Street, Suite 425, Newport Beach, CA 92660

**UNITED STATES DISTRICT COURT  
 CENTRAL DISTRICT OF CALIFORNIA**

THE TAWNSAURA GROUP, LLC

PLAINTIFF(S),

v.

TWINLAB CORPORATION

DEFENDANT(S).

CASE NUMBER

SACV12-1467 SJO(AGRx)

**PROOF OF SERVICE - ACKNOWLEDGMENT  
 OF SERVICE**


I, the undersigned, certify and declare that I am over the age of 18 years, employed in the County of ORANGE, State of California, and not a party to the above-entitled cause. On October 22, 2012, I served a true copy of FIRST AMENDED COMPLAINT FOR PATENT INFRINGEMENT by personally delivering it to the person (s) indicated below in the manner as provided in FRCivP 5(b); by depositing it in the United States Mail in a sealed envelope with the postage thereon fully prepaid to the following: (list names and addresses for person(s) served. Attach additional pages if necessary.)

Place of Mailing: Daniel S Silverman, Venable LLP, 2049 Century Park East, Suite 2100, Los Angeles, CA 90067

Executed on October 22, 2012 at Newport Beach, California

Please check one of these boxes if service is made by mail:

- I hereby certify that I am a member of the Bar of the United States District Court, Central District of California.
- I hereby certify that I am employed in the office of a member of the Bar of this Court at whose direction the service was made.
- I hereby certify under the penalty of perjury that the foregoing is true and correct.

  
 \_\_\_\_\_  
 Signature of Person Making Service

**ACKNOWLEDGEMENT OF SERVICE**

I, \_\_\_\_\_, received a true copy of the within document on \_\_\_\_\_.

\_\_\_\_\_  
 Signature

\_\_\_\_\_  
 Party Served